It has been a turbulent few months for biotech startups trying to list their shares on the public markets. First, a profligate 2018 turned sour for initial public offerings, with the average debutant down more than 20 percent by year’s end. Then, the record-setting federal shutdown forced a dozen or so would-be success stories to sit on their hands as market regulators stayed at home and unpaid.

Now, with the government back open, biotech has its Punxsutawney Phil in the form of Alector, a 6-year-old company hoping to convince the world that its novel approach to Alzheimer’s disease is worth a $1.4 billion valuation. And, with five other biotech firms angling to go public this month, Alector’s offering — expected to price this week — has become a closely watched barometer of what 2019 might have in store for the drug development industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy